Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.72 |
| ▸ | TEK | Q02763 | 14/20 | 0.72 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.51 |
| ▸ | YES1 | P07947 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 2/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12542963 | 0.82 | KDR (0.67) | KDRTEKDDR2YES1BRAF | |
| SCHEMBL1264048 | 0.82 | TEK (0.75) | KDRTEKYES1BRAF | |
| SCHEMBL1264967 | 0.81 | KDR (0.71) | KDRTEKYES1BRAF | |
| SCHEMBL1264649 | 0.81 | TEK (1.00) | KDRTEKYES1 | |
| SCHEMBL4782834 | 0.81 | KDR (0.64) | KDRTEKDDR2YES1BRAF | |
| SCHEMBL1264319 | 0.80 | KDR (1.00) | KDRTEKYES1 | |
| SCHEMBL1266008 | 0.79 | KDR (0.76) | KDRTEKYES1 | |
| SCHEMBL1265774 | 0.79 | TEK (0.84) | KDRTEKYES1BRAF | |
| SCHEMBL1263938 | 0.78 | TEK (0.81) | KDRTEKYES1BRAF | |
| SCHEMBL1265062 | 0.78 | KDR (0.67) | KDRTEKYES1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236823-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2012-08-07 | — | — | US | claimed |
| US-8822514-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822514-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822514-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-8236823-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236823-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236823-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20080255205-A1 | protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255205-A1 | protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255205-A1 | protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008057280-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057280-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | TIE1, FLT4, CDK1 | KDR 4/4885TEK 11/4885DDR2 345/4885 |
| US-20080255205-A1 | protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide | TIE1, AURKB, TEK | KDR 5/4885TEK 3/4885DDR2 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.